Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,428
Total Claims
$2.4M
Drug Cost
408
Beneficiaries
$5,828
Cost/Patient
Risk Score Breakdown 7/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-60%
Opioid rate vs peers
0.9% vs 2.2% avg
+313%
Cost per patient vs peers
$5,828 vs $1,411 avg
+112%
Brand preference vs peers
22.5% vs 10.6% avg
Opioid Prescribing
0.9%
Opioid Rate
111
Opioid Claims
$247
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,573 claims · $2.1M
Generic: 8,856 claims · $206K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 191 | $292K |
| Semaglutide | 154 | $277K |
| Budesonide/Formoterol Fumarate | 343 | $217K |
| Sitagliptin Phos/Metformin Hcl | 132 | $176K |
| Dapagliflozin Propanediol | 130 | $153K |
| Dulaglutide | 70 | $113K |
| Insulin Aspart | 99 | $109K |
| Insulin Glargine,hum.Rec.Anlog | 117 | $87K |
| Sitagliptin Phosphate | 52 | $85K |
| Umeclidinium Bromide | 108 | $63K |
| Sitagliptin Phos/Metformin Hcl | 38 | $51K |
| Fluticasone Propion/Salmeterol | 54 | $50K |
| Linagliptin/Metformin Hcl | 38 | $46K |
| Fluticasone/Vilanterol | 48 | $43K |
| Apixaban | 52 | $41K |
Prescribing Profile
Patient Profile
65
Avg Age
69%
Female
1.28
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data